

Matthias Gutfleisch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3353986/publications.pdf>

Version: 2024-02-01

16
papers

378
citations

1039406

9
h-index

794141

19
g-index

22
all docs

22
docs citations

22
times ranked

393
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinically applicable deep learning-based decision aids for treatment of neovascular AMD. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260, 2217-2230.	1.0	8
2	Frequency of retinal detachment after surgical treatment of full-thickness macular holes with 23-gauge pars plana vitrectomy. Acta Ophthalmologica, 2021, 99, e441-e442.	0.6	1
3	<p>Quantitative Comparison of the Vascular Structure of Macular Neovascularizations Between Swept-Source and Spectral-Domain Optical Coherence Tomography Angiography</p>. Clinical Ophthalmology, 2020, Volume 14, 3179-3186.	0.9	3
4	Analysis of the Vascular Morphology of the Fibrotic Choroidal Neovascularization in Neovascular Age-Related Macular Degeneration Using Optical Coherence Tomography Angiography. Klinische Monatsblatter Fur Augenheilkunde, 2020, 237, 1312-1319.	0.3	1
5	Morphologic analysis of macular neovascularizations by OCT angiography—Technical limitations in the comparison of 3Å–3mm and 6Å–6mm images. PLoS ONE, 2020, 15, e0237785.	1.1	2
6	RANIBIZUMAB IN PIGMENT EPITHELIAL TEARS SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina, 2019, 39, 2369-2377.	1.0	5
7	Optical coherence tomography angiography of types 1 and 2 choroidal neovascularization in age-related macular degeneration during anti-VEGF therapy: evaluation of a new quantitative method. Eye, 2019, 33, 1466-1471.	1.1	33
8	Changes in the OCT angiographic appearance of type 1 and type 2 CNV in exudative AMD during anti-VEGF treatment. BMJ Open Ophthalmology, 2019, 4, e000369.	0.8	17
9	NEGATIVE EFFECTS OF VITAL DYES AFTER UNEVENTFUL VITREOMACULAR SURGERY. Retina, 2019, 39, 1772-1778.	1.0	4
10	Characteristics of type 1 and 2 CNV in exudative AMD in OCT-Angiography. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 913-921.	1.0	75
11	RETINAL PIGMENT EPITHELIAL TEAR AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION. Retina, 2016, 36, 868-874.	1.0	21
12	ASSOCIATION BETWEEN CHANGES IN MACULAR VASCULATURE IN OPTICAL COHERENCE TOMOGRAPHY- AND FLUORESCIN- ANGIOGRAPHY AND DISTRIBUTION OF MACULAR PIGMENT IN TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA. Retina, 2015, 35, 2307-2316.	1.0	33
13	Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme. Graefe's Archive for Clinical and Experimental Ophthalmology, 2011, 249, 639-644.	1.0	47
14	Intravitreal and Orbital Floor Triamcinolone Acetonide Injections in Noninfectious Uveitis: A Comparative Study. Ophthalmic Research, 2009, 42, 81-86.	1.0	44
15	Foveal RPE autofluorescence as a prognostic factor for anti-VEGF therapy in exudative AMD. Graefe's Archive for Clinical and Experimental Ophthalmology, 2008, 246, 1229-1234.	1.0	20
16	Pars plana vitrectomy with intravitreal triamcinolone: effect on uveitic cystoid macular oedema and treatment limitations. British Journal of Ophthalmology, 2007, 91, 345-348.	2.1	43